Sign up to save your podcasts
Or
Share JAMA Oncology : Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
JAMA Oncology : Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD.
View all episodes
By The JAMA Network
4.9
1212 ratings
Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD.
More shows like JAMA Network
View all
JAMA Editors' Summary
128 Listeners
Neurology® Podcast
287 Listeners
NEJM This Week
318 Listeners
JAMA Author Interviews
162 Listeners
Diabetes Core Update
97 Listeners
Practical Neurology Podcast
35 Listeners
JAMA Clinical Reviews
485 Listeners
Mayo Clinic Talks
271 Listeners
JAMA Cardiology Author Interviews
9 Listeners
JAMA Dermatology Author Interviews
17 Listeners
JAMA Internal Medicine Author Interviews
19 Listeners
JAMA Psychiatry Author Interviews
22 Listeners
JAMA Medical News
83 Listeners
Core IM | Internal Medicine Podcast
1,091 Listeners
Psychiatry & Psychotherapy Podcast
1,320 Listeners
JAMAevidence The Rational Clinical Examination
29 Listeners
Annals On Call Podcast
184 Listeners
The Clinical Problem Solvers
508 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
JAMAevidence JAMA Guide to Statistics and Methods
19 Listeners
The Curious Clinicians
362 Listeners
AMA Update
98 Listeners